Drug intelligence / Profile preview

Covidiol Syrup

Development stage: Preclinical
Lead developer: Cannabis Bioscience International
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**Covidiol Syrup** is an orally administered preclinical phytocannabinoid syrup being developed by Cannabis Bioscience International for COVID-19. The program is described as aiming to modulate the immune response during SARS-CoV-2 infection; no defined molecular target, individual active phytocannabinoid, or detailed pharmacologic mechanism has been publicly specified.

Other names: Covidiol Syrup

Beyond the preview

Go deeper on Covidiol Syrup.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Covidiol Syrup.

Explore the full profile